Available online at www.sciencedirect.com
SCIENCE DIRECT®
European Journal of Pharmacology 465 (2003) 201
www.elsevier.com/locate/ejphar

Corrigendum

Corrigendum to "Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352" [Eur. J. Pharmacol. 437 (2002) 129–137]☆

Delphine S. Dupuis[a,b], Rikke L. Schrøder[b,c], Thomas Jespersen[a], Jeppe K. Christensen[b], Palle Christophersen[b], Bo S. Jensen[b], Søren P. Olesen[a,b,*]

[a] *Department of Medical Physiology, University of Copenhagen, The Panum Institute, 3 Blegdamsvej, DK 2200 Copenhagen N, Denmark*
[b] *NeuroSearch A/S, 93 Pederstrupvej, DK 2750 Ballerup, Denmark*
[c] *University, 7 Frederik Bajersvej, DK 9220 Ålborg E, Denmark*

In the above-mentioned article, the compound used and referred to as BMS-204352 is, however, not the pure S-enantiomer described by Gribkoff et al. (Nat. Med., 7(4): 471–7, 2001) but the racemic mixture (50%) of the S- and R-forms called Compound 1 by Gribkoff et al. The misconception is entirely due to an internal communication error at NeuroSearch where the compound was resynthesised. The author apologizes for the inconvenience.

☆ PII of original article S0014-2999(02)01287-6.

* Corresponding author. Poseidon Pharmaceuticals A/S, 93 Pederstrupvej, Ballerup DK-2750, Denmark. Tel.: +45-44-60-87-77; fax: +45-44-60-87-87.
E-mail address: spo@poseidonpharma.com (S.P. Olesen).

doi:10.1016/S0014-2999(03)01436-5